Clinical trial
Rheumatoid Arthritis DMARD Intervention and UtilizationStudy
NCT00116727 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00116727 |
|---|---|
| Title | Rheumatoid Arthritis DMARD Intervention and UtilizationStudy |
| Official title | Rheumatoid Arthritis Disease Modifying Anti-Rheumatic Drug (DMARD) Intervention and Utilization Study (RADIUS 2) |
| Lead sponsor | Amgen, Industry |
| Collaborators | Immunex Corporation Industry Wyeth is now a wholly owned subsidiary of Pfizer |
| Status | Completed |
| Study type | Observational |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | ENBREL® |
| Enrollment | 5,103 |
| Start date | Oct 1, 2002 |
| Primary completion | Jun 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Jul 1, 2005 |
| Last update posted | May 6, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: